Metabolic Syndrome and Insomnia

By | March 30, 2016
Subjective and objective markers used together to monitor progress with a participatory model of health care.

Metabolic Syndrome Objective markers indicate recovery and are used together with subjective self-reporting (see Insomnia Recovery chart, below) to monitor progress in a participatory model of health care.

Comorbidities are expected and occurring with greater frequency in US adults.  In fact, a recent study showed that in the United States, there is now a prevalence of multiple chronic conditions (MCC) in 26% of adults which has increased from 21% ten years before.[1]  One such MCC relationship that has recently been noted in the scientific medical literature is the association between Insomnia and Metabolic Syndrome.  In this article by Kim in Sleep Medicine, it was concluded, “Short sleep duration is an independent risk factor for incident metabolic syndrome in a population-based longitudinal study.” [2]

 In the present case study, all subjects began the Marshall Protocol® (MP) to manage their chronic inflammatory and autoimmune conditions.  All subjects began olmesartan medoxomil in an off-label manner, at a higher and more frequent dosing schedule, typically 40mg every six hours as indicated on the graph.   This was in accordance with FDA “Off-Label and Investigational Use” guidelines.[3]  All subjects were palliated with the usual standard of care (SOC) medications prior to the start of the MP.  All SOC medications were discontinued at the start of the MP in most cases.  They utilized olmesartan medoxomil alone, invoking immunostimulation.

There were 47 out of 62 or 76% of the subjects who self-reported insomnia.  Metabolic Syndrome was present in 48 of 62 subjects or 77% confirmed with laboratory testing of: Cholesterol, triglycerides, fasting insulin, HDL, FSH and LH.  The co-morbidity of Insomnia and Metabolic Syndrome was present in 38 of 62 subjects or 61%.   The graph on the left demonstrates a group of eight subjects: 6 females and two males who had metabolic syndrome by objective laboratory findings.  In this smaller group, only two subjects reported no insomnia.  Over the individual timelines, there was resolution of Metabolic Syndrome shown by objective clinical evidence and Insomnia by self-report in these eight subjects.

In the Insomnia Recovery/Olmesartan Medoxomil only group, there were 10 males and 33 females self-reporting insomnia.   Time to recovery varied by subject but for the majority of females and males, Insomnia symptom reduction occurred in the first year and recovery happened, for most, by 2 years.

Insomnia recovery

Insomnia self reporting progress, along with objective markers for metabolic syndrome, shows a fuller description of recovery in a participatory model of health care. (As seen on 2016 Leipzig poster presentation.) 


[1] Prevalence of multiple chronic conditions among US adults: the National Health Interview Survey 2010, ward, Brian W. et al.  Prev Chronic Dis, 2013; 10.

[2] A prospective study of total sleep duration and incident metabolic syndrome: the ARIRANG study, Kim, Jang-Young et al. Sleep Medicine , Volume 16 , Issue 12 , 1511 – 1515.

[3] “Off-Label” and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices – Information Sheet, http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm